Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

June 28, 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

June 21, 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.

June 21, 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.

June 14, 2023

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

May 30, 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

May 24, 2023

A panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.

May 17, 2023

Sunandana Chandra, MD, MS, Anna C. Pavlick, DO, MSc, MBA, BSN, and Nikhil Khushalani, MD, discuss the importance of multidisciplinary care in CSCC and patient counseling regarding available therapies.

May 17, 2023

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

May 17, 2023

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

May 10, 2023

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

May 10, 2023

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

May 05, 2023

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

May 03, 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

May 03, 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

April 28, 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

April 28, 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

April 26, 2023

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

April 26, 2023

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

April 21, 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

April 21, 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.